0.14
+0.89%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MindMaze Therapeutics Holding
Its shares trade on SIX under the ticker MMTX.SW. It has been listed since 19 September 2011. In the fiscal year to 31 December 2025, it reported revenue of CHF 642,000 and a net loss of CHF 9.9m. At that date it held total assets of CHF 51.5m and shareholders' equity of CHF 38.3m.
RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. The company is headquartered in Geneve, Geneve. The company went IPO on 2011-09-19. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. The company specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The firm is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Sept 2011
- Employees
- 24
- Website
- relieftherapeutics.com ↗
Leadership
Pay as last reported
- Dr. Raghuram SelvarajuChairman of the Board, since 2016CHF 187,248
- Mr. Jeremy MeinenChief Financial Officer
- Mr. Giorgio ReinerChief Scientific Officer
- Mr. Paolo GalfettiChief Business Officer, since 2021CHF 70,833
- Mr. Vincenzo GalloHead of Legal and Compliance
- Mr. Peter De SvastichDirectorCHF 96,000
- Mr. Thomas ElzingaDirectorCHF 80,000
- Mr. Gregory Van BeekDirectorCHF 144,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 53
- Environment
- 55
- Social
- 75
- Governance
- 30
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Clinical-stage biotechnology company with 24 employees in Geneve
- Lead compound RLF-100 in phase 2b/3 trials for respiratory diseases
- Natural origin molecules with clinical use history and efficacy data
Weaknesses
- Limited employee count of 24 full-time staff
- IPO in 2011 with no recent expansion
- Single lead compound RLF-100 for multiple indications
Opportunities
- Phase 2b/3 trials for RLF-100 in COVID-19 respiratory deficiency
- Development of RLF-100 for pulmonary sarcoidosis
- Planning stage for acute and chronic lung disease indications
Threats
- No recent clinical trial updates beyond 2011
- Dependence on single compound RLF-100 for multiple diseases
- Lack of additional pipeline products beyond RLF-100
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.